BRAF and non-small cell lung carcinoma: Additionally, breakthroughs include inhibitors targeting ALK, ROS1, BRAF, RET, and NTRK, alongside the recent integration of immune checkpoint pathway inhibitors in both second-line and front-line treatments for NSCLC.7It is crucial to highlight that these immunotherapy strategies necessitate the alignment of known antigens or pathways with specialized antibodies.